Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

518
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
518
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

608
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
608
Drug Therapy01:28

Drug Therapy

83
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
83
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

27
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
27
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

28
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
28

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

Migraine: from pathophysiology to treatment.

Journal of neurology·2023
Same author

Evaluating migraine with typical aura with neuroimaging.

Frontiers in human neuroscience·2023
Same author

Non-invasive neuromodulation of the cervical vagus nerve in rare primary headaches.

Frontiers in pain research (Lausanne, Switzerland)·2023
Same author

Effectiveness and safety profile of greater occipital nerve blockade in cluster headache: a systematic review.

Journal of neurology, neurosurgery, and psychiatry·2023
Same author

Patient-reported experiences with migraine-related cognitive symptoms: Results of the MiCOAS qualitative study.

Headache·2023
Same journal

The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.

eNeurologicalSci·2026
Same journal

Correlation of the monocyte to high-density lipoprotein cholesterol ratio and neutrophil to high-density lipoprotein cholesterol ratio with the severity of acute ischemic stroke.

eNeurologicalSci·2026
Same journal

Painful tic convulsif: Dual neurovascular compression within the spectrum of cranial nerve hyperactive dysfunction syndromes.

eNeurologicalSci·2026
Same journal

Nitrous oxide-related neurotoxicity: Clinical features, key investigations, and a proposed diagnostic approach from a single-center cohort.

eNeurologicalSci·2026
Same journal

Fractures beyond spasms: Progressive encephalomyelitis with rigidity and myoclonus associated with GABA-linked bone fragility.

eNeurologicalSci·2026
Same journal

Response to "Comment on 'Prevalence and risk factors of paediatric seizures in COVID-19 infection: A study from Thailand'".

eNeurologicalSci·2026
See all related articles

Related Experiment Video

Updated: Aug 14, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.3K

Headache: Treatment update.

Oyindamola I Ogunlaja1, Peter J Goadsby1,2

  • 1NIHR King's Clinical Research Facility and SLaM Biomedical Research Centre, King's College London, UK.

Eneurologicalsci
|January 13, 2023
PubMed
Summary
This summary is machine-generated.

New migraine treatments like ditans and gepants offer alternatives for patients unable to use triptans. Anti-CGRP monoclonal antibodies are best for those with treatment-resistant or intolerant migraines.

Keywords:
MigraineResource limited settingsTreatment

More Related Videos

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

8.2K
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

3.9K

Related Experiment Videos

Last Updated: Aug 14, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.3K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

8.2K
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

3.9K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a leading cause of global disability.
  • Significant efforts have focused on developing targeted migraine therapies.

Purpose of the Study:

  • To review emerging migraine treatments.
  • To discuss the place of new therapies in clinical practice, considering cost and patient profiles.

Main Methods:

  • Review of recently approved migraine medications.
  • Analysis of drug classes: 5HT1F receptor agonists (ditans), CGRP receptor antagonists (gepants), and anti-CGRP monoclonal antibodies.

Main Results:

  • New drugs include lasmiditan (a ditan), gepants (ubrogepant, rimegepant, atogepant), and anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab).
  • Lasmiditan and gepants are suitable for moderate-to-severe migraines in patients who cannot tolerate triptans due to side effects or contraindications.
  • Anti-CGRP antibodies are recommended for patients who have not responded to or tolerated multiple conventional preventive treatments.

Conclusions:

  • Novel migraine therapies offer valuable options for specific patient groups.
  • Cost and patient history are crucial factors in selecting appropriate migraine treatments, especially in resource-limited settings.